Sign in

Trial result ·

A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions.

Written based on 1 research study on PubMed, searched on 3 Nov 2026.

What was studied

This was an early-stage trial of a vaccine called VTP-200. It was tested in women with long-lasting high-risk HPV and past low-grade cervical lesions. The vaccine uses a 2-vector plan. Doses were given on day 0 and day 28. An open-label start phase came first. Then 99 women were chosen at random to 5 dose groups or placebo. The main goal was safety. Others were immune response and clearing of virus and lesions at 12 months.

What they found

The regimens were well tolerated. There were no grade 3 treatment-related events or serious reactions. All doses led to T-cell responses against HPV. The virus cleared in 20 of 64 people on the vaccine. It cleared in 10 of 30 people on placebo. That gap was not significant. Lesion clearance did not differ either. A trend to higher clearance was seen with the highest doses of one vector. The immune response in blood was not linked to clearance.

What it means for patients

The authors say the regimen was well tolerated and set off immune responses. They say it did not significantly clear the virus or the lesions.

Why it is not certain yet

This was an early-stage trial. The gap in virus clearance between vaccine and placebo was not significant. The higher clearance with the highest doses was only a trend. No link was shown between immune response and clearance. The abstract gives 99 people in the main phase.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions.

PubMed · PMID 41403292

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Cervical cancer publications